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Abstract Components of purinergic signalling are expressed
in the early embryo raising the possibility that ATP, ADP and
adenosine may contribute to the mechanisms of embryonic
development. We summarize the available data from four
developmental models—mouse, chick, Xenopus and zebra-
fish. While there are some notable examples where purinergic
signalling is indeed important during development, e.g. de-
velopment of the eye in the frog, it is puzzling that deletion of
single components of purinergic signalling often results in
rather minor developmental phenotypes. We suggest that a
key step in further analysis is to perform combinatorial alter-
ations of expression of purinergic signalling components to
uncover their roles in development. We introduce the concept
that purinergic signalling could create novel morphogenetic
fields to encode spatial location via the concentration of ATP,
ADP and adenosine. We show that using minimal assump-
tions and the known properties of the ectonucleotidases, com-
plex spatial patterns of ATP and adenosine can be set up.
These patterns may provide a new way to assess the potential
of purinergic signalling in developmental processes.
Keywords Embryogenesis.Neurulation.Gastrulation.
Organogenesis.Morphogen.ATP.Adenosine.ADP
Introduction
ATP has a central role as the universal energy store in cellular
metabolism. However, ATP is also used as an extracellular
signallingmoleculeinmanydiversecontexts[1,2]—including
in the peripheral organs, the brain and most relevant to the
context of this review, during embryonic development.
ATP can act at both ionotropic (P2X) [3] and metabotropic
receptors (P2Y) [4]. However, it differs from many other
chemical signalling agents in the body in that it can be broken
downintheextracellularspacetoanumberofothermolecules
some of which retain biological signalling activity at distinct
sets of receptors. For example, the first breakdown product,
ADP, can act at P2Y1, P2Y12 and P2Y13 receptors [4].
Adenosine, a later product in the extracellular catabolic cas-
cade can act at four distinct G-protein-coupled receptors (A1,
A2A,A 2B and A3)[ 5]. The extracellular enzymes that control
the metabolism of ATP in the extracellular space, therefore do
much more than terminate the actions of ATP, they can also
initiate the actions of downstream signalling molecules. In
considering the potential roles of purinergic signalling during
development, it is therefore very important to take into ac-
count not just the various receptor families, but also the
diverse enzyme families that break down ATP. There are at
least four gene families that encode ectoenzymes relevant to
the breakdown ofATP.These includethe ENTPDases(related
to CD39), the ENPPases, alkaline phosphatases and ecto-5′
nucleotidase (5′NT, also known as CD73) [6, 7].
The complexity of purinergic signalling has the potential
to offer new mechanisms to control developmental events.
During embryogenesis, pluripotent cells become progres-
sively restricted to one fate. These differentiated cells are
then organised inside a tissue or organ where they are
specialised for particular functions. Cell-to-cell interactions,
some of which will be mediated by diffusible signals, play
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generation and arrangement of these distinct specialised cell
types. Exemplars of all the components of purinergic sig-
nalling display specific expression patterns during very ear-
ly development. This suggests that developmental processes
may indeed avail themselves of the potential complexity
inherent in purinergic signalling.
In this review, we shall not consider data obtained in vitro
or in postnatal studies. Instead, we shall focus on the four
vertebrates that are extensively used as models in develop-
mentalbiology:chick,mouse,Xenopus and zebrafish (Fig. 1).
We do not intend to present a comprehensive overview of
purinergic signalling during neuronal development. We refer
the readers to other very good reviews [8–10]. Instead, we
seek to address the potential roles of purinergic signalling
more generally in very early development.
Our aim is to present a novel view on how purinergic
signalling may act during embryogenesis. We start first by
briefly summarizing the four major developmental models,
and then consider in detail the expression profile during
development of the major purinergic components, i.e. the
ectonucleotidases and the purinergic receptors. After this, we
review the phenotypes induced following alteration (genetic,
pharmacological) of key components of purinergic signalling.
We then consider from a more theoretical perspective the
potentialofpurinergicsignallingagentsasnovelmorphogens.
To do this, we firstly consider an established morphogen,
retinoic acid (RA), and then by comparison demonstrate
how simulations incorporating known properties of the ecto-
nucleotidases can result in spatial patterns of ATP and aden-
osine to provide the potential for morphogenetic fields of
greater complexity than those described for RA.
Models of development
As many coming to this field may not be fully familiar with
the four developmental models (chick, mouse, Xenopus and
zebrafish) that we consider in our review, we shall give a
brief account of their embryonic development. This is im-
portant because we wish to establish common development
stages between the four models ultimately to allow abstrac-
tion of general principles with regard to the contribution of
purinergic signalling. As the four model organisms develop
Fig. 1 Comparative embryogenesis of the mouse, chick, Xenopus and
zebrafish. After fertilization (F), these four vertebrates undergo similar
phases during their embryonic life. Species-specific stages are indicat-
ed on the figure. Briefly, Mouse embryos will implant (imp) at E4.5,
after formation of the blastocyst and separation between the epiblast (or
primitive ectoderm), at the origin of the embryo, and the cells which
will give rise to the extra embryonic structures, the trophoectoderm and
the primitive endoderm. The turning process, at E9, allows the estab-
lishment of the dorsal and ventral axis. The organogenesis is followed
by the embryonic or foetal growth phase and birth takes place between
18 to 21 days after fertilization, depending on the mouse strain. The
cleavage phase of the Chick embryos takes place in the hen oviduct.
After laying, gastrulation and neurulation are complete in 2 days and
stage HH14 is characterized by the existence of 22 somites. Feather
germs appear at stage HH30 and organogenesis and embryo growth
continue till hatching 22 days after fertilization. Cleavage of Xenopus
embryos will be complete by stage 9, blastula stage and neurulation
starts at stage 12.5 and ends at stage 20. First somite is formed at stage
17. Organogenesis is the longest phase, characterized by the hatching
of the embryos from their vitelline membrane around stage 25. After
stage 45, the tadpole will start feeding and will undergo the metamor-
phosis phase before becoming an adult frog. Zebrafish embryos dis-
play the quickest embryonic life cycle. Cleavage divisions lead to the
formation of a blastoderm lying over the yolk, at the sphere stage, 4 h
after fertilization. Gastrulation starts 5.5 h after fertilization, at the
shield stage and is complete only 4.5 h later. Somite formation and
neurulation follow during the segmentation period. Organogenesis then
takes place during the pharyngula period, less than 24 h after fertiliza-
tion, and zebrafish embryo usually hatches 48 to 72 h after fertilization.
The term larva is being arbitrarily used after the end of the third day,
whether the hatching has taken place or not
504 Purinergic Signalling (2012) 8:503–521rather differently and on very different timescales, this can
be a challenge for newcomers to developmental biology.
The four vertebrate model organisms commonly used for
developmental work have distinct advantages and disadvan-
tages, which are summarized in Table 1. Being the only
mammalian model with a relatively short embryonic life
cycle of 3 weeks together with the ease of making genetic
modifications, the mouse has become a model of choice for
many developmental biologists. However, the inaccessibil-
ity of the embryo and the difficulty of in vivo manipulation
is a serious technical barrier for investigation of gene func-
tion during early development phases.
Avian embryos are very similar to the mammalian ones in
the general course of embryonic development, and as the
embryo is accessible, are very good for manipulative em-
bryology. However, the development is not external and
chick embryos are quite difficult to breed.
Xenopus and zebrafish embryos exhibit external devel-
opment, rapid generation times and are easy to maintain.
These embryos therefore display great advantages as models
for development. A unique complication of Xenopus laevis
is that the genome is pseudotetraploid, rather than diploid.
Whereas, this genome has not been sequenced, that of
Xenopus tropicalis has, and this close relative has the ad-
vantage of a diploid genome [11].
Despite their anatomical and embryonic cycle length
differences, a broadly similar set of developmental stages
can be defined for these 4 vertebrate models (Fig. 1). After
fertilization, the zygote undergoes cleavage. This stage is
composed by rapid cell divisions, initially without an in-
crease in overall mass of the embryo. The pattern of these
divisions is quite diverse depending on the yolk richness and
distribution in the egg. However, this cleavage period leads
to a formation of cell mass whose shape differs, but is
equivalent to the Xenopus blastula. Xenopus embryos de-
velop from the entire egg mass whereas the zebrafish em-
bryo develops only around the large mass of yolk. Chick
and mouse embryos derive from a layer of epithelium called
the epiblast as other cells will be involved in the formation
of extra embryonic structures. This stage is followed by
gastrulation, the fundamental process which shapes the
features of the developing animal with the induction of the
three germ layers: ectoderm which will give rise to the
epidermis and neural tissues, endoderm which will generate
the digestive tube and accessory organs and mesoderm
which will form muscles, cardiovascular and skeletal ele-
ments [12]. This process involves four major evolutionary
conserved morphogenetic movements (internalization, epib-
oly, convergence and extension), which allow the internali-
zation of the mesodermal and endodermal cells whereas the
ectodermal cells surround the embryo. Inductive processes
specify and pattern these germ layers, which are controlled
by the key signalling centre called the organizer (Spemann–
Mangold centre in Xenopus, the embryonic shield in zebra-
fish, the Hensen's node in chick and the node and AVE
(anterior visceral endoderm) in mouse). Onset of gastrula-
tion is characterized by the appearance of the blastopore,
which marks the future dorsal side of the Xenopus embryo
and in zebrafish by the formation of the shield-shaped
region, indicating the shield stage. Chick and mouse gastru-
lation is marked by the convergence of the epiblast cells
towards the primitive streak, similar to the amphibian blas-
topore. Gastrulation is then followed by neurulation, the
formation of the neural tube. Notochord and somites, at
the origin of the vertebrate column and trunk and limbs
muscles, are formed or start to appear during the neurula
stage.
Although early developmental phases differ, all verte-
brate embryos pass through the phylotypic stage, the stage
at which they all look rather similar and exhibit the specific
features of chordate embryos (a neural tube running along
the dorsal midline on top of the notochord flanked on either
side by the somites). Organogenesis comprises the final
embryonic stage and will allow the formation of internal
organs and specific features such as beaks, wings, legs, fins.
Reliable ways of identifying specific developmental
stages are essential for the analysis of embryonic develop-
ment. The easiest method is the time from fertilization.
Mouse embryos are most often referred to by their embry-
onic age (E) days post coitum, since their temperature is
constant. However, they can be staged according to criteria
described by Theiler [13] or by Downes and Davies [14].
However, time from fertilization cannot be used for Xenopus
embryos as their developmental speed is temperature depen-
dent. Other criteria, based on embryonic morphology, have
been developed and are described in the tables of Nieuw-
koop and Faber [15]. Numbered stages, known as HH stages
(Hamburger and Hamilton), mostly based on the number of
somites, have been identified for chick embryos [16]. Zebra-
fish embryos are identified by the criteria published by
Kimmel et al. [17], especially during the first 24 h.
The key comparison across the four models in under-
standing gene expression patterns is not the absolute time of
development, but the developmental stage. With accurate
staging, it becomes possible to normalize the different de-
velopmental stages thus allowing comparison of the pattern
of expression of purinergic signalling components across
the different models (Fig. 2).
Expression patterns during early development
It is self-evident that to influence early development, a gene
must be expressed at an appropriate time. Therefore, the
logical beginning of any investigation into whether puriner-
gic signalling plays a role in embryogenesis resides in
Purinergic Signalling (2012) 8:503–521 505determining the expression patterns of its key players, the
ectonucleotidases and purinergic receptors.
Several studies have been performed to characterize the
spatial and temporal expression profile of purinergic signal-
ling components in developing embryos (Table 2, Fig. 2).
These data demonstrate that there is indeed potential for
ATP, ADP and adenosine-mediated signalling to be in-
volved at all stages, from cleavage to organogenesis. How-
ever, an important point is the extent to which these studies
are comprehensive—absence of evidence is not the same as
evidence of absence. Therefore we also list studies that
demonstrate the lack of expression of several receptors and
enzymes during embryonic development (Table 3).
Most data are available for the mammalian embryos.
However, few of these studies have investigated the expres-
sion of these genes in the entire embryo, and most have
focussed on one specific organ. One useful way of deter-
mining expression patterns is to generate a knock-out (KO)
by insertion of the β-gal gene into the relevant locus. The
expression of lacZ is directly under the control of the pro-
moter of the gene of interest, thus lacZ expression easily
demonstrates the expression profile of the mutated gene. Sev-
eral KO mice of purinergic signalling components have been
generated in this way. Disappointingly, however, the distribu-
tion of lacZ staining throughout embryogenesis has not been
reported [18–24]. We suggest that use of this tool would be a
relatively easy and extremely useful way to determine the
expression of these genes in the entire mouse embryo.
Purinergic receptors
Table 1 Characteristics, advantages and disadvantages of the four major vertebrate model organisms
Chick Mouse Xenopus Zebrafish
Development Internal (oviduct for
cleavage stage)/external
In utero External External
Developmental specificity Early development like
mammals (primitive streak)
Mammalian Metamorphosis Early development phases
quite different to other
vertebrates.
Developmental cycle
length
22 days 18–21 days 4 days (at 23°C),
temperature dependent
2–3 days
Offspring <10 <10 10
3 10
2
Oocyte size (diameter) 2.5 cm 80–100 μm 1.2–1.4 mm 0.7 mm
Maintenance and
breeding
Easy but need to obtain
laid eggs
Difficult and expensive Very easy Very easy
Manipulative embryology Access through the egg shell
(graft, beads implantation)
Only for embryos up to
blastocyst stage but
need to be re-implanted
Microsurgery, graft,
fate mapping
Microsurgery, fate
mapping
Genome Sequenced (1.2×10
9) Sequenced (3×10
9) Tetraploid genome not
yet sequenced but
X tropicalis genome
(1.8×10
9) sequenced
Sequenced (1.7×10
9)
duplicated genome
Genetics based
techniques
Spontaneous mutations, gene
silencing (RNAi), electroporation,
transgenic animal (lentivirus),
ES cells
Electroporation, KO, KI,
conditional
transgenesis
Gene silencing (MO),
gain of functions
(injection RNA,
protein, DNA),
transgenic animal
(REMI)
KO, gene silencing and
gain of functions as
Xenopus embryos but no
targeted injections
Screens Mutation screens (but costly
and difficult)
Mutation screens Pharmacological and
mutation screens
Pharmacological and
mutation screens
Specific advantages Chimera ES cells, iPS Targeted injections, high
resistance to infections
Transparency of embryos
Website MGI Xenbase ZFIN
ES embryonic cells, iPS induced pluripotent cells, KO knock-out, KI knock-in, MO morpholino oligonucleotide, REMI restriction enzyme-
mediated insertion
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Most of the purinergic receptors are expressed in the mouse
embryo at some point (Fig. 2). However, this survey is not
comprehensive as some of these data come from databases
[25, 26] (BGEM website: http://www.stjudebgem.org/web/
mainPage/mainPage.php; Eurexpress website: http://www.
eurexpress.org/ee/) for which expression has only been in-
vestigated at one or two embryonic stages. Except for P2X3
[27], most of the information available comes from the
stages of organogenesis and foetal growth. This may be
due to difficulty of extracting mouse embryos before E7/
7.5, the start of neurulation.Expressed Sequence Tag (ESTs) databases have been
generated for in silico analysis. The UniGene database
(http://www.ncbi.nlm.nih.gov/UniGene) gives information
for each gene about its transcripts and ESTs, genomic loca-
tion and expression. Although being developed in several
vertebrate species, the database for mouse is one of the most
advanced. Analysis of the UniGene for purinergic receptors
clearly indicates expression of these receptors at all embry-
onic stages of mouse embryos especially during the early
phases. ESTs have been identified for P2X3, P2X4, P2Y1,
A1 and A2b during zygote, cleavage and gastrula stages.
Fewer P2 and P1 receptors have been cloned in chick,
Xenopus and zebrafish. Nevertheless, expression studies
have demonstrated the presence of P2X, P2Yand adenosine
receptors from gastrulation stages, suggesting that ATP,
ADP and adenosine may also play a role during very early
phases of development in non-mammalian species. The
comparative expression profile of the P2X genes demon-
strated that these receptors have distinct patterns of expres-
sion during zebrafish development suggesting specific roles
for each P2X receptor subtype [28]. Adenosine signalling
may also be important in early development as A1 and A2
receptors are expressed from the gastrulation stage in chick
and zebrafish embryos respectively [29].
Interestingly, there is evidence that P2X5, P2Y12, P2Y13
and P2Y14 are not expressed at E14.5, during organogene-
sis [26] (Table 3). However, ESTs for P2Y12 and P2Y13
have been identified in organogenesis and foetal growth
stages. Transcripts for P2Y13 have been identified at stage
E12 and ESTs for P2Y12 cloned from mouse embryos at
stages E10.5, E14.5 and E16, suggesting that these two
receptors may be involved in embryogenesis. Although
these data seem contradictory, RT-PCR is a more sensitive
technique than in situ hybridization and allows the detection
of weakly expressed transcripts, whose expression may be
below the detection level of the in situ hybridization tech-
nique. However, no ESTs have been cloned for P2X5 and
P2Y14 during mouse embryogenesis (Table 3), although
P2X5 channels are present in the developing rat skeletal
muscle from E15 [30]. This would suggest either that there
are differences of expression between the two rodent species,
or that P2X5 is expressed in the developing mouse embryo at
a later stage. Mouse P2X7 expression has been detected by in
situ hybridization although no clear expression profile can be
drawn, maybe due to weak expression or a ubiquitous signal
[26]. No specific staining for P2X7 has also been observed in
zebrafish embryos [28]. The staining evident at 24hpf was
widespread, confirming the possible ubiquitous expression of
this receptor during vertebrate embryogenesis.
Ectonucleotidases
Strikingly, the expression ATP-hydrolysing ectoenzymes is
detected from very early phases of embryonic development.
In Xenopus, Massé et al. carried out two comparative ex-
pression studies for the ENTPDase and ENPP family
Fig. 2 Temporal pattern of expression of the purinergic signalling
components in mouse, chick, Xenopus and zebrafish embryos. The
extent of expression of purinergic receptors and ectonucleotidases is
mapped along the major phases of embryogenesis, cleavage, gastrula-
tion, neurulation and organogenesis and embryo growth that have been
normalized in duration for the four model organisms to allow easier
comparison. The expression of some of these genes has only been
described at one stage (indicated by arrows). EST expression data is
indicated by blue dashed lines and corresponding gene names in blue.
The expression of mouse genes published in [25]o r[ 26] as part of the
embryonic mouse database and atlas of gene expression are indicated
by solid blue lines. The murine P2Y1 expression by in situ hybridiza-
tion is available on the MGI website
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Gene Detection methods Expression domains References
Rodents
A1 ISH (rat) Heart, neural tissues, kidney [98, 99]
A2A ISH (mouse) Neural tissues [25]
A2B ISH (mouse) Neural tissues [25]
A3 ISH (mouse) Aorta and heart [57]
P2X family RT-PCR (rat) Distinct expression profile in developing brain [100]
P2X family RT-PCR (rat) P2X2, 3, 4 and 7 in developing
inner ear tissues
[101]
P2X1 Immunostaining/ISH RT/PCR
(mouse)
In the pancreas, liver, gut, bladder and aorta [26, 102][ 103]
P2X2 ISH (mouse) Nervous system (brain and ganglia) [26]
P2X3 Immunostaining (mouse) Neuronal (sensory ganglia) and non neuronal tissues [26, 41, 104][ 27]
Microarray/RTqPCR Higher in blastocysts than morula and 4-cell stages
P2X2/P2X3 Immunostaining (rat) P2X3 from E11, P2X2 from E14. In NS and non
neuronal tissues (kidney)
[105, 106]
P2X4 ISH (mouse) Brain, nose, skin, muscle, skeleton [25, 26]
P2X2, 5 and 6 Immunostaining (rat) In developing skeletal muscle tissues [30]
P2X7 Immunostaining (rat) In developing pancreas [107]
P2X7 ISH (mouse) No regional signal [26]
P2Y1 RT-PCR (mouse) Entire embryo pool [108]
P2Y2 ISH (mouse) No regional signal [26]
P2Y6 ISH (mouse) No regional signal [26]
ENTPD2 ISH (mouse) Ganglia and PNS [26]
ENTPD3 ISH (mouse) Wide expression [26]
ENPP1 ISH (mouse) Nervous system, Tooth [25, 26]
ENPP2 ISH (mouse) Nervous system and various organ primordia [25, 33, 34]
5′NT ISH (mouse) Mesenchyme [26]
TNAP RT-PCR/ISH/immunostaining/
histochemical (mouse)
Early phases; brain precursor cells; skeleton [26, 109, 110, 111]
EAP RT-PCR Restricted to early phases (until blastocyst) [109, 112]
Xenopus
A1 Electrophysiology, pharmacology Spinal cord [113]
A2A ISH Somites and eyes. [61]
P2Y1 ISH/Northern blot Brain, spinal cord, eyes, somites [114]
RT-PCR From cleavage stages. K. Massé and N. Dale,
unpublished data
P2Y8 Northern blot/ISH Neural tissue [115]
P2Y11 RT-PCR/ISH Mesoderm and derivatives, nervous system, placodes [116]
ENTPD family RT-PCR/ISH Distinct expression profile for ENTPD1,2 and 3 [32]
ENPP family RT-PCR/ISH Distinct expression profile for ENNP1, 2a, 2b and 3 [31]
Zebrafish
A2A, 2B ISH Distinct expression pattern; 2 A2 receptors [29]
P2X3 ISH From 6-somite stages, Rohon beard neurons [42]
P2X family ISH P2X1, P2X3.1, P2X3.2, P2X4.2, P2X8 are expressed
but P2X5, P2X7 are not expressed in neural tissues.
[28]
P2X3.1/P2X3.2 ISH Restricted pattern in sensory neurons [43]
ENTPD3 ISH Brain and spinal cord (Rohon beard neurons) [44]
508 Purinergic Signalling (2012) 8:503–521members [31, 32]. Each member displays a distinct expres-
sion profile. ENTPD1, 2 and 3 are not maternal genes and
their zygotic expression is switched on from either gastru-
lation or the end of neurulation. However ENPP1, 2a, 2b
and 3 are all maternal suggesting that nucleotide hydrolysis
can occur during the early phases of development. In mouse
embryos, only the ENPP2 expression profile has been
reported in detail [33, 34]. ESTs for several murine enzymes
have been identified at the zygote stage (ENTPD2 and
ENPP2) and in the blastocyst stage (ENTPD1, ENPP1,
ENPP3). Recent evidence suggests that the role of ENPP2
or autotaxin protein during vertebrate physiology and em-
bryogenesis may be more related to its ability to generate
bioactive lipids, such as LPA, than to its activity in hydro-
lyzing ATP [35]. Not many studies report the expression of
ectonucleotidases in chick embryos, but ESTs have been
identified for ENTPD1, ENTPD2, ENPP1 and CD73.
There are few reports on the expression of the CD73 (or
5′NT) enzyme at embryonic stages. EST counts on the
NCBI website and in situ hybridization [26] suggest expres-
sion during organogenesis. This is quite interesting consid-
ering that increased levels of adenosine signalling during
cleavage can be lethal [36], suggesting that vertebrate em-
bryos may limit adenosine production during the very ear-
liest phases of embryogenesis. However, this role of 5′NT
could conceivably be fulfilled by other enzymes such as the
alkaline phosphatases, which are also expressed during
mammalian embryogenesis. The embryonic alkaline phos-
phatase (EAP) predominates during the very early phases of
development, whereas tissue non-specific alkaline phospha-
tases (TNAP) predominate after implantation stages. Pros-
tatic acid phosphatase (PAP) [37, 38] is also potentially
relevant as it is widely expressed in adult non-prostatic
tissues, in particular in adult rat and in mouse nociceptive
dorsal root ganglia (DRG) neurons [39, 40]. No study has
yet investigated systematically the expression profiles of
these enzymes during embryonic development but tran-
scripts have been described in early phases of vertebrate
development: oocyte, zygote and cleavage stages for mouse
embryos; and neurula stages for Xenopus embryos. However,
Table 2 (continued)
Gene Detection methods Expression domains References
Chick
A1 RTqPCR In Hensen's node and heart primordia (HH4) [60]
A3 RT-PCR (adult) Brain and muscle [117]
P2X1 Northern blot Highest expression in lung, none in brain and eyes [118]
P2X4 RT-PCR In brain and heart tissues, from day4 (HH23) [119]
P2X5 ISH/Northern blot somites, heart, brain [120]
P2X5/P2X6 Immunostaining Muscle and only P2X5 in nervous system [121]
P2X5 ISH/Northern blot Nervous system, eye, heart, digestive tract and muscle [122]
P2Y1 Northern blot spinal cord and muscle [123]
Northern blot/ISH Mesoderm derivatives and CNS [124]
ENPP2 ISH NS, somites, limb bud. [34]
Gene duplication events have been described in Xenopus and zebrafish for enpp2 and the P2X family, giving rise to extra subtypes of these genes
ISH in situ hybridization, CNS central nervous system, PNS peripheral nervous system
Table 3 Components of purinergic signalling that are not expressed at
some or all stages of vertebrate embryogenesis
Gene Method Stages References/Websites
Mouse
A3 ISH E8.5, E12.5 [57]
P2X5 ISH/EST E14.5 [26] Eurexpress;
NCBI
P2Y12 ISH E14.5 [26] Eurexpress
P2Y13 ISH E14.5 [26] Eurexpress
P2Y14 ISH/EST E14.5 [26] Eurexpress;
NCBI
PAP ISH E14.5 [26] Eurexpress
Xenopus
ENTPD8 RT/PCR All stages [32]
ENTPD1,3 RT/PCR Before end of
neurulation
[32]
ENTPD2 RT/PCR Before gastrulation [32]
P2Y8 Northern
blot
Before neurulation [115]
P2Y11 RT/PCR Before gastrulation [116]
Zebrafish
P2X2, P2X4.1 ISH 24 and 48 hpf [28]
ENTPD3 ISH Before 23hpf [44]
Chick
P2X5 ISH At stage HH11 [120]
Purinergic Signalling (2012) 8:503–521 509in situ hybridization failed to detect mouse PAP transcripts at
later phases [26].
Emergent common principles
Although most of these genes are expressed in the neural
tissues and sensory organs, expression has also been
reported in somites and muscle tissues, heart, kidney and
gastrointestinal organs (Table 2). This demonstrates that
purinergic signalling may be involved in the formation of
all three germ layer derivatives (ectoderm, mesoderm and
endoderm).
As the expression studies of the purinergic components
across the four model organisms are incomplete, it is difficult
to abstract general principles of expression during embryo-
genesis. However, some common principles can be outlined.
ENTPD8 seems to be the only ectonucleotidase that is not
expressedduringmouseembryogenesisasnoESTshavebeen
identified for this gene during these developmental stages.
Moreover, no ESTs for this gene have been cloned during
chick, rat, human and zebrafish embryogenesis and it is not
expressed during Xenopus embryogenesis [32].
The P2X3 receptor is expressed in DRG in mouse [41]
and Rohon beard neurons in zebrafish, which display func-
tional homology to mammalian DRG neurons [28, 42, 43],
suggesting a conserved role for this receptor during evolu-
tion. However, major differences can also be noted. For
example, murine ENTPDase3 displays a wide expression
profile at E14.5 [26] that differs from the tissue-restricted
expression seen in spinal cord of zebrafish and Xenopus
embryos [32, 44].
Further work is needed to generate more comprehensive
comparative expression profiles for each of these receptors
and enzymes that document expression of these components
at specific tissues and developmental stages. This is a nec-
essary step for in vivo functional studies and ultimately for a
better understanding of purine roles during embryogenesis.
Analysis of purinergic mechanisms in development
Establishing a causal link between purinergic signalling and
development depends on far more than determination of
expression patterns. Demonstration of causality requires
perturbation of some aspect of purinergic signalling and
analysis of resultant phenotype. This can be accomplished
via genetic or pharmacological methods. Genetic methods
include constitutive and inducible gene knock-out or over-
expression. The use of siRNA and antisense oligonucleoti-
des, such as morpholino oligonucleotides (MO) is also
possible with frog and zebrafish embryos. Pharmacological
methods have the advantage of simplicity and rapidity.
However, highly selective agents that target specific
components of purinergic signalling are not always avail-
able, and application of these agents to the correct stages of
development and organs/tissues may be problematic.
Genetic manipulations in mice
A number transgenic knock-out mice lacking expression of
particularreceptorsandenzymeshavebeengenerated(Table4).
For the most part, these mice have not been generated for the
specificpurposeof analysis of development.Rather,thesemice
have been made to allow analysis of physiological function in
the adult. This means that detailed data on the effect of these
knock-outs on development is not necessarily available. Nev-
ertheless,astrikingandperhaps puzzling observationis that the
majority of receptor-mutant mice are viable, fertile and do not
display any gross morphological abnormality.
The phenotypes of these single mutant mice are usually
confined to a small subset of tissues, with studies mostly
focusing so far on the physiology of the nervous, the excre-
tory or hematopoietic systems. The absence of any reported
developmental phenotypes for single gene mutations might,
at first sight, suggest that purinergic signalling does not play
an essential role during embryogenesis. Nevertheless, these
are mainly constitutive mutations and the possibility of
compensatory changes in the expression of other genes to
rescue normal development remains plausible. Furthermore,
the majority of the studies have not investigated whether
morphological defects occur during embryonic life.
One proxy of whether embryonic development is affected
is to analyze whether the percentage of homozygous mice
born is similar to the expected Mendelian rate. For some
strainse.g.P2Y4
−/− orP2X2
−/−the numberofknock-out mice
born was significantly lower than expected [45, 46], suggest-
ing a possible in utero death for the homozygous mice.
There are seven P2X receptor subunits. Thus, loss of one
receptor subunit could plausibly be compensated by over-
expression of another of similar functionality. Double gene
knock-outs can partly address this possibility. For example,
double P2X2/P2X3 KO mice exhibit 90% lethality with
major organ abnormalities, such as enlarged hearts, marked
atrophy of lymphohaematopoietic organs [46]. These phe-
notypes were not observed in single P2X2 and P2X3
mutants [46, 47]. This possibility is even more plausible
where physiologically active heteromeric receptors exist.
For example, the P2X2 subunit can be incorporated into
heterotrimers with P2X3 subunit [48]. If one of the subunits
is deleted, it could be replaced functionally by a homomeric
receptor. This may explain why the knock-out of both P2X2
and P2X3 subunits has a far greater phenotype and lethality
than deletion of either subunit individually.
Itisalsoimportanttonotethatthelossofonegivenspecific
receptor does not necessarily induce the up-regulation of
expression of the related receptors. For example, deletion of
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Gene Studies Phenotype References
Mouse
A1 KO Behavioural/Physiological Increase of aggressiveness; defects in TGF [20, 125]
A2A KO Behavioural/Physiological/histological Increase of aggressiveness and blood pressure;
Neuroprotection, No neuronal developmental defects
[126, 127]
A2B KO Physiological Inflammation responses [23, 128]
A3 KO Physiological Defects in inflammatory responses. [49]
P2X1 KO Physiological Male infertility [19]
P2X2 KO Physiological/Behavioural/ No gross phenotype [46]
P2X3 KO Physiological Defects in pain responses and bladder function [18, 47]
Behavioural
P2X2/P2X3 KO Physiological/behavioural Lethal (at P7) and defects in sensory response [46]
P2X4 KO Physiological Defects in vascular tone and remodelling; Defects
in synaptic potentiation; involvement in recruited
macrophages
[21, 22, 129]
P2X7 KO Physiological Defects in cytokine production, in pain response [130, 131]
P2Y1 KO Physiological Defects in platelet aggregation and thrombosis [52, 53]
P2Y2 KO Physiological (isolated cells or organs) Defects in calcium and chloride transport [132, 133]
P2Y4 KO Physiological (isolated organs) Defects in chloride transport [45]
P2Y6 KO Physiological (isolated cells and
trachea)
Defects in UDP response in macrophages,
VSM and endothelial cells.
[134]
P2Y12 KO Physiological Defects in platelet thrombosis [135, 136]
P2Y13 KO Physiological Defects in cholesterol metabolism [137]
P2Y14 KO Physiological Defects in stomach muscle contractility [24]
ENTPD1 KO Physiological Defects in hemostasis and thromboregulation [138]
5′-NT KO Physiological (in vivo and isolated
cells or nephrons)
Defects in TGF [139, 140]
ENPP1 ENU mutagenesis Defects in mineralization and calcification [141]
ENPP1 Spontaneous mutation Defects in ossification [142]
ENPP2 KO Developmental Lethal (E9.5), defects in neural system and
vascular development
[143, 144]
PAP KO Physiological Increase of nociceptive responses [37]
TNAP KO Developmental Lethal(before weaning) Defects in bone
mineralization and neural tube abnormalities
[145]
EAP KO Developmental Delay in development; blastocyst degeneration;
reduction in litter size
[146]
A1 KI (cardiac promoter) Physiological Lethal (between 6 and 12 weeks) congestive
heart failure
[56]
A3 KI (muscle promoter) Histological Lethal (before E8.5) [57]
Adenosine In vitro culture Blocks development at the 2-cell stage. [36]
Xenopus
MO ENTPD2 Developmental Loss of eye [51]
MO P2Y1
P1 receptor agonists Developmental Defects in somite formation; reduction of
myoD expression
[61]
P1 receptor antagonists Pharmacological screen Defects in angiogenesis and lymphangiogenesis [147]
P2 receptor antagonists Developmental Defects in gastrulation, formation of
ventralized embryos
[148]
Zebrafish
MO P2X3.1 Developmental Defects in craniofacial development and
sensory circuit formation
[55]
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A1,A 2A or A2B receptors in mice [49]. Furthermore, the loss
of A2B or P2X3 receptor subunits does not alter expression of
other adenosine or P2X receptors [18, 50].
Lower vertebrates
Xenopus and zebrafish have the great advantage of allowing
easy access to very early developmental stages. In both of
these models, there is the possibility of combinatorial micro-
injections of mRNAs, proteins and MO allowing gain and
loss of function making them advantageous models to deci-
pher the complexity of the purinergic signalling pathway.
Moreover, targeted injections are possible in Xenopus, en-
abling to target one specific tissue or organ allowing study
of gene function in vivo when mis-expression in the whole
embryo is lethal.
Massé et al. demonstrated that ADP controls eye forma-
tion by regulating the expression of the eye field transcrip-
tion factor (EFTF) gene network at stage 12.5, just
following the end of gastrulation [51]. It is worth pointing
out that the effects due to P2Y1 mis-expression were mild
and could have been unnoticed without careful experimental
design and measurement. In these experiments, gene manip-
ulation was unilateral thus giving internal controls (non-
manipulated side) for comparison in each embryo. Equally
mis-expression of ENTPDase2 while giving much greater
phenotypes than mis-expression of the P2Y1 receptor was
unable to prevent eye formation. By contrast, simultaneous
knockdown of the P2Y1 receptor and ENTPDase2 com-
pletely ablated eye formation. This may be an important
general message for the analysis of purinergic signalling in
development: combinatorial deletion or knockdown of func-
tionally linked components may be essential to uncover
phenotype and hence developmental roles.
So far, there is no evidence that a similar purinergic mech-
anism for eye development pertains to mouse. P2Y1
−/− new-
bornmice have eyes[52, 53], as do mice lacking ENTPDase2
(unpublished observation, Kristine Gampe, Herbert Zimmer-
mann, Simon C. Robson). However the expression of these
components should be studied from the start of the neurula-
tion,asearlyasstageE7.5.ThisisbecausemurinePax6(akey
EFTF gene) is first detected at stage E8 in the head neural
ectoderm, including the optic pit, the first morphologically
detectable indication of the eye region [54]. By analogy with
Xenopus, it may also be necessary to perform combinatorial
deletions of P2Y1 and ENPTDase2 to uncover a major eye
phenotype in mouse.
Further evidence for the role of ATP signalling in lower
vertebrate development comes from the knockdown of
P2X3 receptor in zebrafish. This leads to defects in cranio-
facial development and sensory circuit formation [55].
However, no such phenotype is observed in P2X3
−/− mice
[18, 46]. It is possible that the two genes do not fill the same
functions in the two organisms. Nevertheless, as these genes
display the same expression profile in zebrafish and mouse,
we think it likely that the discrepancy between these phe-
notypes may be due to one of the reasons discussed above.
Adenosine signalling and development
In contrast to the apparent tolerance of development to
alteration of P2 receptors and even deletion of single ecto-
nucleotidases, a striking observation is that modification of
adenosinergic signalling can have powerful effects on de-
velopment. The overexpression of the adenosine A1 receptor
under the control of a cardiac promoter is lethal postnatally
due to defects in the heart [56]. Perhaps more interesting
developmentally is the overexpression of the A3 receptor
under the control of a muscle promoter [57]. This is lethal
Table 4 (continued)
Gene Studies Phenotype References
Chick
P1 receptor agonists Developmental Defects in heart looping [60]
Adenosine Physiological Defects in vascular development [59]
Other organisms
Starfish
Adenosine Developmental Blocks development at the 256-cell stage. [58]
Dictyostelium
Quintuple dP2X KO Disruption of intracellular calcium signalling [149]
dP2X KO Defects of osmoregulation [150]
For mouse, only papers referring to mouse transgenic generation are listed
KO knock-out, KI knock-in, MO morpholino antisense oligonucleotide knock down of expression, TGF tubuloglomerular feedback, VSM vascular
smooth muscle
512 Purinergic Signalling (2012) 8:503–521by E8.5. Application of exogenous adenosine blocks mouse
and starfish development during the cleavage phase [36,
58]. Furthermore, exogenous adenosine receptor agonists
induce several developmental defects in Xenopus and chick
[59–61]. The lack of major phenotypes in 5′NT KO mice
might be explained by the existence of other enzymes able
to generate adenosine from AMP. Interestingly, KO mutant
mice for EAP and TNAP display developmental phenotypes
(Table 4).
Adenosine deaminase (ADA) is a potentially important
mechanism for the removal of adenosine through conver-
sion to inosine. During mouse embryogenesis, expression of
ADA is not detected in the embryo before E7, although
ADA activity is detected in the placenta [62]. Expression
levels of ADA increase during E7 and E9 in the mouse
embryo. From E15, ADA is expressed in the thymus,
spleen, gut and kidney [63]. ADA
−/− mice die perinatally
at E19 [64, 65]. ADA-deficient patients suffer from severe
immunodeficiency but also display several neurological ab-
normalities [66].However, this neurological phenotype could
also be explained by a non-enzymatic function of the
ectoADA, which by binding to the A1 receptor and the
CD26 protein,could be involvedin cell–cell interactions[67].
Purinergic signalling and development—a new synthesis
So far, withone ortwo exceptions, manipulationofpurinergic
signalling (at least of single signalling components) has sur-
prisingly small effects on development. One reason for this
might be that these mechanisms simply are not important for
development. Nevertheless, the developmentally specific ex-
pression of key components that for some is present and
similar in each of the four model systems suggests to us that
such an absolutist position is not easily tenable. Instead, we
wish to explore whether there are deeper mechanistic reasons
as to why the role of purinergic signalling has not yet been
convincingly established more generally.
Morphogenetic gradients and chemical signalling
during development
Despite the complexity of elaborating an organism from a
single cell, rather few signalling pathways seem to be in-
volved in embryogenesis. In effect, the embryo possesses a
small ‘tool kit’ and uses the same factors repeatedly at
different times and locations during embryogenesis. Some
of these signalling molecules are morphogens—defined as
molecules that can act directly on cells to produce specific
responses (usually activation of target genes) that depend on
morphogen concentration [68]. The key point is that morph-
ogens diffuse from their source to produce a concentration
gradient that encodes position. Cells read their position
within this concentration gradient and determine their de-
velopmental fate accordingly.
The Notch signalling pathway acts via the activation of
the Notch receptor by membrane-bound ligands that are
members of the Delta or Serrate families [69]. However,
the majority of the morphogens are soluble proteins, which
can be grouped into a few families based on their structures.
The major families are the hedgehog family, the fibroblast
growth factors family, the wingless (or Wnt) family and the
transforming growth factor (TGF)-β superfamily, which
includes, among other proteins, the TGF-β family, the acti-
vin family, the bone morphogenetic proteins and the nodal
and nodal-related proteins [70–73].
The specificity of the functions of each member of these
families is due to their expression pattern and the availabil-
ity of their specific receptors. It can be seen from this that
both the mechanism of producing the morphogen and ex-
pression of the receptors for the morphogen are critical to
correct operation of this signalling mechanism.
RA is a non-protein morphogen derived from vitamin A
or retinol and is responsible for all of the biological activity
associated with this vitamin. During development, RA is
involved in somitogenesis as well as central nervous system
patterning and neuronal differentiation [74]. These actions
are mediated by heterodimers of two nuclear receptors, the
retinoic acid receptors (or RARs) and retinoid X receptors
(RXR), although the RA-binding specificity relies on the
RAR receptors [75]. These heterodimers bind to the RARE
DNA sequences and can activate for example the transcrip-
tion of homeobox-containing genes.
The various morphogenetic signalling systems do not act
in isolation but instead interact with each other to construct
the different organs during vertebrate development, as for
example during the development of the vertebrate limb [76].
We now consider the extent to which the purines can be
considered as morphogens.
Evidence supporting the purines as morphogens
Several criteria need to be satisfied for a substance to be
considered as a morphogen. Firstly, the molecule should be
present at the right place and time and must be released from
a localized source to allow formation of a concentration
gradient. The available evidence suggests that the purines
meet this criterion. In vivo measurements using specific
biosensors have demonstrated in Xenopus that ATP is in-
deed specifically released in the anterior neural plate but not
in the posterior neural plate, just before eye field specifica-
tion [51]. ATP, ADP and adenosine gradients would there-
fore be shaped and generated by the activity of the
ectonucleotidases (see also Fig. 3 below).
Secondly, gene expression should depend upon morphogen
concentration. The morphogen gradient will thus control
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increase of extracellular ADP (by overexpression of
ENTPDase2) induced ectopic Pax6 expression and ectopic
eyes [51]. By contrast, a reduction of ADP (by knockdown
of ENTPDase2 or overexpression of ENTPDase1) reduced
Pax6 expressionin the eyefield andcan prevent eye formation
[51].Therefore,ADPatleastmeetsthesecondofthesecriteria.
More generally as there are many different receptor subtypes
for ATP, ADP and adenosine each having different affinities
for their respective agonists, it is plausible that they could
mediate concentration-dependent cell-specific actions.
Finally, the actions of a morphogen should be direct (i.e.
cell autonomous). No studies have yet demonstrated direct
induction of gene expression via activation of purinergic
receptors in a developmental context. This is a key outstand-
ing issue for the definitive classification of purines as
morphogens: can purinergic receptors directly alter gene
expression in a concentration dependent manner during
development and if so, what signalling pathways mediate
this action? An intriguing possibility is that mobilization of
intracellular Ca
2+ via the activation of purinergic receptors
(such as P2Y1) could mediate changes in gene expression
and also act to link the purinergic pathways with those of
other established morphogens such as Wnt which has an
established Ca
2+-sensitivity [71]. However, there are prece-
dents for purinergic receptors acting on other pathways
involved in the regulation of gene expression. For example,
several purinergic receptors can alter the activity and ex-
pression of the transcription factor NFκB[ 77–82]. Activa-
tion of both adenosine and ATP receptors will induce
phosphorylation of the CREB, a key step in its activation
and ability to bind to the cAMP response element, and thus
also have the potential to alter gene expression via this
pathway [83–86].
As they meet two of the three essential criteria, we
propose purines as putative morphogens. Whether they meet
the third criterion has not yet been estabished or refuted.
Parallels between RA and purinergic pathways
The most similar established morphogen to the purines is
RA (like the purines it is a low molecular weight diffusible
molecule) and we shall therefore explore this signalling
system further.
The availability of the bioactive RA is controlled by
specific enzymes allowing its synthesis and degradation.
RA is synthetized from retinol in two steps of oxidation,
each catalyzed by different families of enzymes. The first
step is the reversible and rate limiting conversion of retinol
to retinal by an alcohol dehydrogenase and short-chain
dehydrogenase/reductase of which retinol dehydrogenase
10 (RDH10) is the most important during development
[87]. The second step is the irreversible oxidation of retinal
to RA by enzymes of the aldehyde dehydrogenase family
also known as retinal dehydrogenase (RALDH).
During development, RALDH2 is considered to be the
predominant enzyme and responsible for the production of
nearly all embryonic RA [88]. RA is then degraded into a
wide variety of oxidized metabolites, such as 4-oxo-RA or
4-HO-RA. The Cyp26 family controls the catabolism of
RA. Although some studies have suggested potential bio-
logical functions for these downstream metabolites, the
principal role of Cyp26 proteins is to degrade RA and
therefore terminate RA-induced effects. This places Cyp26
and the metabolic enzymes of RA as the major regulators of
the RA signalling pathway by restricting its availability and
establishing strictly controlled domains of RA distribution
in order for embryonic development to properly occur
(reviewed in [89]). Therefore, the concept of RA acting as
Fig. 3 Simulation of diffusion and metabolism of ATP—a complex
purinergic morphogenetic field. The simulation (values shown at T05s
after beginning) shows that ATP and ADP are locally high in concen-
tration over the first 30–40 μm, but that adenosine peaks at around
60 μm and remains high in concentration up to around 120 μm. Thus a
complex pattern is produced where the potential for ATP/ADP actions
is bounded and limited by a zone where adenosinergic actions have the
potential to predominate. The simulation considers a short strip of cells
(inset) where one cell at the end releases ATP; the ATP is then
converted successively through the intervening intermediates to aden-
osine, with feed-forward inhibition of the final step mediated by ATP
and ADP (inset top). All the metabolites diffuse along the strip with the
same diffusion coefficient (300 μm
2/s). The conversion of ATP and
metabolites are described by Michaelis–Menten kinetics, based on
literature values [93–95]: ATP, Km 33.3 μM, Vmax, 100 μM/s; ADP,
Km 9.5 μM, Vmax 20 μM/s; AMP, Km 0.94 μM, Vmax,2 0μM/s; both
ATP and ADP inhibit the conversion of AMP to adenosine (Ado) with
ak i of 0.1 μM. The simulation is based on the following parallel linked
equations: ∂[ATP]/∂t0D ∂
2[ATP]/∂x
2−k1[ATP]; ∂[ADP]/∂t0D
∂
2[ADP]/∂x
2+k1[ATP]−k2[ADP]; ∂[AMP]/∂t0D ∂
2[AMP]/∂x
2+
k2[ADP]−k3.ki[AMP]; and ∂[Ado]/∂t0D ∂
2[Ado]/∂x
2+k3.ki[AMP].
Where D is the diffusion coefficient, and k1,k 2 and k3 are rates based
on the Michaelis–Menten kinetics given above. These equations were
solved numerically using code written for Matlab. We thank Dr. Mag-
nus Richardson for assisting us with this code
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encompass Cyp26 as the main constraint for defining areas
of RA-induced gene expression [90].
The importance of RA-metabolising enzymes during em-
bryogenesis has been demonstrated by generation of KO
mice for these enzymes. Mice lacking RDH10, RALDH2
or Cyp26a die during embryonic life and exhibit severe
patterning defects and morphological abnormalities [87,
88, 91]. Surprisingly, null mutants for the RA receptors
RARα,R A R β,R A R γ remain viable and the observed
abnormalities are restricted to a subset of tissues (reviewed
in [92]). However, in utero lethality and severe developmen-
tal defects are observed in double RAR transgenic mice
revealing an extensive functional redundancy within the
members of each family. This is not surprising considering
the existence of several RA receptor isoforms, the various
tissues combinations of RAR/RXR expression during em-
bryogenesis. It should be remembered however that RAR/
RXR alter gene expression by binding directly to specific
DNA sequences. The purinoreceptors if they do indeed
directly regulate gene expression during embryogenesis
would have to achieve this via second messenger pathways.
Striking parallels can thus be drawn between the RA and
purinergic signalling pathways. Both of them are character-
ized by: (1) the activation of multiple receptor subtypes and
potential receptor redundancy; and (2) the control of the
availability of the bioactive molecules by catabolizing
enzymes which exhibit developmentally selective expres-
sion. In both cases, it seems necessary to delete more than
one receptor subtype to observe major developmental
defects. And in both, deletions of single degradative
enzymes seem to give more profound phenotypes than
deletion of single receptors.
However, the purinergic system offers potential for great-
er complexity of morphogenetic signalling than does the RA
system. This is because the ectonucleotidases that terminate
the effects of ATP-induced effects also initiate the effects of
the downstream molecules, ADP and adenosine, via the
inactive precursor, AMP.
Unique features of purines as putative morphogens
The kinetics of the ectonucleotidases are complex and sug-
gest interesting possibilities for the formation of morphoge-
netic fields by purines. For example, it is well known that
the ecto-5′ nucleotidase (5′-NT) undergoes feed-forward
inhibition by ADP and ATP [93]. This has previously been
proposed to provide temporal separation between the re-
lease of ATP and the appearance of adenosine [94, 95]. This
temporal separation is functionally possible because one of
the intermediates on the way to adenosine, AMP has no
action at either P1 or P2 receptors. Thus AMP can act as an
inactive store for the delayed production of adenosine.
It occurred to us that the same mechanisms would also
provide spatial separation between the release of ATP and
the production of extracellular adenosine. Consider a simple
model with a linear row of cells with a cell at one end of this
row releasing ATP (Fig. 3, inset). The ATP will diffuse
along the row of cells dropping in concentration with dis-
tance from the source. If the ectoATPases and ecto-5′NTare
uniformly distributed, then close to the source of the ATP,
the final step in the production of adenosine from AMP
would be rather slow as a result of the feed-forward inhibi-
tion of ecto-5′NT. With increasing distance from the site of
release the concentrations of ATP and ADP will decrease
(by diffusion) allowing the enzymatic production of adeno-
sine to increase in rate. The inactive AMP will have accu-
mulated and hence provide a reservoir production of
adenosine at some distance from the original source of
ATP. Furthermore, as it is not taken up, AMP has the
potential to diffuse further in the tissue prior to breakdown
to adenosine, than adenosine itself which will be removed
from the extracellular space by a variety of concentrative
and equilibrative transporters.
We have performed some elementary simulations (Fig. 3)
to illustrate this idea and confirm that with minimal assump-
tions, the known properties of the components of purinergic
signalling lead to a spatial patterning of ATP and adenosine
levels that is considerably more complex than that afforded
by the RA pathway (which would give a pattern roughly
similar to that of ATP alone).
While our ideas are purely speculative, they do have
three implications. Firstly, they may provide an explanation
as to why alterations of receptor expression by themselves
may not be very efficacious in altering development—the
morphogenetic pattern still remains and can be read by other
related receptors, perhaps with lower efficiency but still well
enough to control development. Secondly, they provide a
reason why mis-expression of the ectonucleotidases may be
more effective in altering development as they will change
the extent and shape of the hypothesized purinergic mor-
phogenetic field. Finally, they provide a way to understand
why overexpression of adenosine receptors and indeed ex-
ogenous adenosine have the tendency to be lethal—these
manipulations by either changing the levels of adenosine
globally, or by altering the sensitivity of adenosine detection
may obscure the extent and shape of the hypothesized
purinergic morphogenetic field.
Temporally defined signalling
Much of the thinking on morphogenetic fields considers
steady-state solutions to the equations governing diffusion
of the morphogens. In this limiting case, the concentration
of morphogen reaches a spatial distribution that does not
vary with time, i.e. ∂c/∂t0D∂
2c/∂x
200.
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release and diffusion of small molecules such a simplifying
assumption of time-invariant fields is probably justified in
many cases. However, our studies on the development of the
eye in Xenopus suggest that rather rapid signalling may also
berelevant.We observeda briefeventofATPreleaseatatime
and location appropriate to trigger the activation of the eye
field transcription factor network. That this brief signalling
event resulted in sustained gene activation comes down to the
characteristics of the gene network and feedback activation
present within the EFTFs. It is unlikely that this is unique to
the EFTFs; transient ATP signalling could be important in
othercontexts.Itisworthreiteratingthateveninthecontextof
transient ATP release, diffusion of ATP away from the source
will conform to the diffusion equation and the enzymatic
kinetics illustrated in Fig. 3. It is therefore highly likely that
a point source of ATP release will be surrounded by an
annulus of adenosine production. If ATP and adenosine were
to have opposing actions on gene induction, such an arrange-
ment might give spatially very precise gene activation.
Concluding remarks
We think that there are several new steps that should be
taken in the analysis of purinergic signalling in early devel-
opment. The first and simplest is that far more comprehen-
sive data on expression patterns needs to be compiled. As
can be seen from our summaries in Tables 2 and 3,t h e
coverage of expression during development is incomplete,
making it hard to draw general conclusions with regard to
patterns common to the four models and to identify the key
groups of developmentally important signalling molecules.
Furthermore, the specificity of expression at a cellular level
in the developing embryo should also be documented. This
step would allow technical approaches that ameliorate the
difficulty of studying early development in mouse embryos.
For example targeted, cell-specific, deletion of purinergic
signalling components mediated via cre-recombinase ex-
pression driven by promoters expressed in the correct cell
types and at the correct developmental stages may enable
much better tests of the roles of purinergic signalling in
development.
Secondly, we suggest that our hypothesis of complex
purinergic morphogenetic fields should be more thoroughly
tested. The key feature of our hypothesis is that there should
be spatial separation between ATP release and adenosine
accumulation. Although electrochemical biosensing meth-
ods for the purines exist [96], perhaps the best way to
investigate this would be with imaging methods as these
afford the possibility of two-dimensional spatial mapping of
analyte concentration with time. The luciferase technique
provides a way of imaging ATP; however, an equivalent
imaging method for adenosine has yet not been devised.
One promising avenue might be to develop FRET-based
biosensors for adenosine [97] utilizing heterologous ex-
pression of adenosine receptors, although these receptors
themselves may perturb development if they remain
functional.
Finally, as different morphogenetic systems interact, it
would be interesting to see whether purinergic signalling
also influences the properties of established morphogenetic
signalling pathways such as Wnt, hedgehog and RA.
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